
NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

Australia COVID-19 Snapshot

	Austra	alia		United States			
	#	# \Delta ^1		#	Δ^1		
Confirmed Cases	28,785	2%		26,166,201	+34%		
Deaths	909	0%		439,517	+30%		
Deaths per 1M	35	0%		1,323	+30%		
Testing rate per 1M	498,911	-		916,573	_		



Participant

Monitoring

COVID-19

Australia Clinical Trial Insights

-026	ihility	
Feas	sibility	

Majority of sites continue to be very interested in new studies

Ethics and Governance

- Bellberry (private EC): continues to operate remotely and is fully operational whilst supporting fast-tracked COVID-19 studies
- Public sites: all meetings conducted virtually and maintaining the pre-planned 2021 timetables. All submissions completed electronically, and legal documents e-signed.

Recruitment

90% of the Top 10 sites are open for recruitment and SIVs for new studies

Participant visits

- Most Top 10 sites are open to subject visits with ongoing social distancing measures
- Sites continue to assess potential for study visits/specific assessments to be completed closer to the participant home to ensure all protocol requirements are met (e.g. local pathology and imaging) including Telehealth and home nursing options
- 80% of all sites are open to either onsite or remote monitoring

Monitoring

- Novotech is working closely with sites with a focus on re-establishing site activities or return to remote monitoring as required
- Novotech is deploying our regionally based CRA teams to ensure continuity with monitoring if local monitors are mandated by

IP Supply and delivery

Significant reduction in passenger jet volume but normal operation of air couriers and local delivery

Site Initiation

- Contingency in place to proactively ensure sufficient IP stock in the country to mitigate any delays with IP supply chain
- Multiple vendors available for Direct to Patient IP delivery and home IP administration, where appropriate
- Australian Health Authority has approved Pfizer vaccine for deployment in February

General

- Electronic signature widely accepted
- Sites, Industry, Health Authority and National HRECs coordinating activities to ensure subject safety and trial continuity
- 100% of Novotech staff can work remotely with office access if required. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation

COVID-19 Trials

High levels of investigator interest, institutional support, and acceleration of processes from Ethics/regulatory authorities

Recruitment

Final protocol to site activation estimated to be 3-4 weeks

Ethics/ Gov

Top 10 sites: High level status (Top 10 sites in Australia represent 33% of biotech activity)

	Etilics/ Gov	Oile iritiation	Recruitment	visits	Worldoning	trials
Westmead Hospital	Available	Available (exceptions)	On hold (exceptions)	Available	Available onsite	Expedited
Monash Hospital	Available	By video	Available (exceptions)	Available	Available onsite	Expedited
The Royal Melbourne	Available	By video	Available	Available	Available onsite	Expedited
Nucleus Network Ltd	Available	Available	Available	Available	Available onsite	Only vaccine trials expedited
Royal Adelaide Hospital	Available	Available	Available	Available	Available onsite	Expedited
The Alfred Hospital	Available	Available	Available	Available	Available onsite	Expedited
Austin Hospital	Available	By video	Available	Available	Available onsite	Requires exec approval
Royal Prince Alfred Hospital	Available	Available	Available	Available	Available onsite	Expedited
Linear Clinical Research	Available	Available	Available	Available	Available onsite	Only vaccine trials expedited
St Vincent's (Melbourne)	Available	On hold (or by video)	Available except for Gastro	Remote visits	Available onsite	On Hold

Novotech monitors activity for all sites. Please contact your project manager for an update -

Sources: Worldometer, Ourworldindata.org, health.gov.au

⁽¹⁾ change versus previous month

NT NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

South Korea COVID-19 Snapshot

	South Korea		United States		
	# \(\Delta^1 \)		#	Δ1	
Confirmed Cases	76.429	+40%	26,166,201	+34%	
Deaths	1,378	+78%	439,517	+30%	
Deaths per 1M	27	+78%	 1,323	+30%	
Testing rate per 1M	106,624	-	 916,573	-	

New cases (left axis) Cumulative cases (right) 1200 60,000 1000 800 40,000 600 400 20,000

22-Oct

08-Dec

COVID-19

03-Jun

Participant

20-Jul

South Korea: New and cumulative COVID-19 cases by notification date

(1) change versus previous month

South Korea Clinical Trial Insights

Feasibility	Majority of sites continue to be very interested in new studies
Ethics and Governance	Review and approval of non-COVID-19 clinical trials are continuing as scheduled
Recruitment	Clinical trial sites are now open and recruitment is ongoing at all trial sites
Participant visits	Subject visits are now available at all sites with social distancing measures implemented
Monitoring	Monitoring visits are permitted at all top sites
IP Supply and delivery	 Normal operation of air couriers and local delivery Contingency in place ensure sufficient IP stock in the country to mitigate any delays with international IP supply chain Multiple vendors available for direct to patient IP delivery as per MFDS guideline
General	 Electronic signature accepted Sites, Industry, Health Authority and ECs coordinating activities to ensure subject safety and trial continuity 100% of Novotech staff can work remotely with office access if required. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation
	The South Korean Ministry of Food and Drug Safety (MFDS) has announced "GO-expedite" program where they are expediting the review process for COVID-19 treatment and vaccine trials with specific timelines. A Novotech client's

COVID-19 Trials

- expediting the review process for COVID-19 treatment and vaccine trials with specific timelines. A Novotech client's COVID-19 trial was approved in under 9 days in South Korea
- High levels of investigator interest and institutional support to participate in COVID-19 trials
- Currently there are 41 COVID-19 trials approved in South Korea. Novotech is involved on two of these projects

Top 10 sites: High level status (Top 10 sites in South Korea represent 48% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	visits	Monitoring	trials
Asan Medical Center	Available	Available	Available	Available	Available	Expedited
Samsung Medical Center	Available	Available	Available	Available	Available (limited seats)	Expedited
Seoul National University Hospital	Available	Available	Available	Available	Available	Expedited
Seoul National University Bundang	Available	Available	Available	Available	Available	Expedited
Severance Hospital, Yonsei University Health System	Available	Available	Available	Available	Available	Expedited
The Catholic University Of Korea Seoul St.Mary's Hospital	Available	Available	Available	Available	Available	Expedited
Pusan National University Hospital	Available	Available	Available	Available	Available for NVT (under MOU)	Expedited
Gachon University Gil Medical C.	Available	Available	Available	Available	Available	Expedited
Chonnam National University Hwasun Hospital	Available	Available	Available	Available	Available	Expedited
The catholic university of korea, st. Vincent hospital	Available	Available	Available	Available	Available	Expedited

Novotech monitors activity for all sites. Please contact your project manager for an update


Sources: Worldometer, Ourworldindata.org


NOVOTECH
The Asia Pacific CRO

Status as at: 25th January 2021

Taiwan COVID-19 Snapshot

	Tai	wan		United States		
	#	Δ1	-	#	Δ^1	
Confirmed Cases	893	+14%		26,166,201	+34%	
Deaths	7	0%		439,517	+30%	
Deaths per 1M	0.3	0%		1,323	+30%	
Testing rate per 1M	6,233	-		916,573	-	





(1) change versus previous month

Taiwan Clinical Trial Insights

Feasibility	Majority of sites continue to be very interested in new studies
Ethics and Governance	Review and approval of clinical trials are continuing as scheduled
Recruitment	Sites are open for recruitment to all trials
Participant visits	Sites are open for subject visits to occur
Monitoring	Monitoring visits are permitted
IP Supply and delivery	No impact and the IP supply chain is operating with no restrictions
General	 100% of Novotech staff can work remotely with office access if required State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation Electronic signatures are now accepted at some sites, however, will require wet-ink signatures when usual practices resume
COVID-19 Trials	 High levels of investigator interest, institutional support, and acceleration of processes from Ethics/regulatory authorities for COVID-19 trials

Top 10 sites: High level status (Top 10 sites in Taiwan represent 78% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
National Taiwan University	Available	Available	Available	Available	Available	Expedited
China Medical University	Available	Available	Available	Available	Available	Expedited
Chang Gung Memorial Hospital- Linko	Available	Available	Available	Available	Available	Expedited
Taipei Veterans General	Available	Available	Available	Available	Available	Expedited
Chang Gung Memorial Hospital Kaohsiung	Available	Available	Available	Available	Available	Expedited
Kaohsiung Medical University Hospital	Available	Available	Available	Available	Available	Expedited
Tri-service General Hospital	Available	Available	Available	Available	Available	Expedited
Chung Shan Medical University Hospital	Available	Available	Available	Available	Available	Expedited
Changhua Christian Hospital	Available	Available	Available	Available	Available	Expedited
Chi Mei Medical Center	Available	Available	Available	Available	Available	Expedited
Taichung Veterans General	Available	Available	Available	Available	Available	Expedited

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org


NOVOTECH
The Asia Pacific CRO

Status as at: 25th January 2021

Hong Kong COVID-19 Snapshot

	Hong k	Cong	United S	United States		
	#	Δ1	#	Δ^1		
Confirmed Cases	10,283	+21%	26,166,201	+34%		
Deaths	175	+29%	439,517	+30%		
Deaths per 1M	23	+29%	1,323	+30%		
Testing rate per 1M	855,378	-	916,573	-		

(1) change versus previous month



Hong Kong Clinical Trial Insights

Feasibility	Majority of sites continue to be very interested in new studies
Ethics and Governance	Review and approval of non-COVID-19 clinical trials are continuing as scheduled
Recruitment	All top 10 sites are open for recruitment
Participant visits	 In public sites, subject visits are proceeding with no changes required There has been limited impact for subjects that reside in China and seen in private sites and institutions
Monitoring	Most sites (public and private) are open for onsite monitoring visits
IP Supply and delivery	No impact and the IP supply chain is operating with no restrictions
General	 Sites, Industry, Health Authority and ECs coordinating activities to ensure subject safety and trial continuity 100% of Novotech staff can work remotely with office access if required. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation Electronic signatures are now accepted at some sites, however, will require wet-ink signatures when usual practices resume
COVID-19 Trials	 High levels of investigator interest, institutional support, and acceleration of processes from ethics/regulatory authorities for COVID-19 trials

Top biotech sites: High level status (Top 10 sites in Hong Kong represent 100% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
Queen Mary Hospital	Available	Available	Available	Available	Available onsite	Expedited
Prince of Wales Hospital	Available	Available	Available	Available	Available onsite	Expedited
Princess Margaret Hospital	Available	Available	Available	Available	Available onsite	Expedited
Queen Elizabeth Hospital	Available	Available	Available	Available	Available onsite	Expedited
Alice Ho Miu Ling Nethersole Hospital	Available	Available	Available	Available	Available onsite	Expedited
Tuen Mun Hospital	Available	Available	Available	Available	Available onsite	Expedited
Humanity & Health Research Center	Available	Available	Available	Available	Available onsite	na
Pamela Youde Nethersole Eastern Hospital	Available	Available	Available	Available	Available onsite	Expedited
Hong Kong United Oncology	Available	Available	Available	Available	Available onsite	na
UNIMED Medical Institute	Available	Available	Available	Available	Available onsite	na

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org


NOVOTECH
The Asia Pacific CRO

Status as at: 25th January 2021

New Zealand COVID-19 Snapshot

	New Zealand		United States		
	#	∆ ¹	#	Δ ¹	
Confirmed Cases	2,295	+8%	26,166,201	+34%	
Deaths	25	0%	439,517	+30%	
Deaths per 1M	5	0%	1,323	+30%	
Testing rate per 1M	300,735	-	916,573	-	

(1) change versus previous month



New Zealand Clinical Trial Insights

Feasibility

Sites continue to be very interested in new studies

Ethics and Governance

- Review and approval of non-COVID-19 clinical trials are continuing as previously scheduled for majority of sites
- Some delays have been observed as a result of staff redeployment, an influx of applications for COVID-19 trials and amendments to existing trials
- Recruitment
- Sites continue to recruit patients across the country
- Participant visits
- Patient visits are ongoing, and sites are continuing to recruit to studies. Healthy volunteers are recruiting to studies

Monitoring

On-site monitoring visits are occurring across New Zealand

IP Supply and delivery

- Tight controls at the borders continue. International commercial flights have been decreased; however, logistic
 companies continue to supply the country
- No restrictions on IP supply to sites by the drug depot
- New Zealand has implemented Alert Level 1 for the whole country on Oct 8th. At level 1 the country has no restrictions on gatherings or travel throughout the country. Regional travel including flying is permitted across the country. Controls at the borders remain for those entering New Zealand, including health screening and testing for all arrivals, and mandatory 14-day managed quarantine or isolation.

General

- Electronic signature widely accepted, now including Indemnities as the need for witness has been removed for the NZACRes template.
- 100% of Novotech staff can work remotely. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation
- MedSafe will be reviewing the Pfizer Covid-19 vaccine application on Feb 2nd 2021

Sita Initiation

COVID-19 Trials

High levels of investigator interest, institutional support, and acceleration of processes from Ethics/regulatory authorities

Docruitmont

Participant

COVID-19

Monitorina

Top sites: High level status (Top 10 sites in New Zealand represent 56% of biotech activity)

Ethics/ Cov

	Etnics/ Gov	Site initiation	Recruitment	visits	Monitoring	trials
Auckland Clinical Studies	Available	Available	Available	Available	Available	Expedited
Auckland City Hospital	Available	Available	Available	Available	Available	Expedited
Christchurch Hospital	Available	Available	Available	Available	Available	Expedited
Middlemore Hospital	Available	Available	Available	Available	Available	Expedited
Christchurch Clinical Studies Trust	Available	Available	Available	Available	Available	Expedited
Clinical Trials New Zealand	Available	Available	Available	Available	Available	Expedited
Dunedin Hospital	Available	Available	Available	Available	Available	Expedited
Christchurch Diabetes Centre	Available	Available	Available	Available	Available	Expedited
New Zealand Brain Research Institute	Available	Available	Available	Available	Available	Expedited

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org


√¶ NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

Thailand COVID-19 Snapshot

	Thailand		United States		
	#	Δ1	#	Δ^1	
Confirmed Cases	15,465	+162%	26,166,201	+34%	
Deaths	76	27%	 439,517	+30%	
Deaths per 1M	1	27%	 1,323	+30%	
Testing rate per 1M	17,423	-	 916,573	-	

(1) change versus previous month



Thailand Clinical Trial Insights

Feasibility •	Sites continue to be ver	y interested in new studies
---------------	--------------------------	-----------------------------

Ethics and Governance

Ethics Committees are accepting new projects online or via a portal as normal

Recruitment

Recruitment is now available at most sites

Participant visits

Sites are open for participant visits

Monitoring

Onsite monitoring visits are restricted until Jan 31st 2021

IP Supply and delivery

- Except for cargo flights, Thailand is closed for international flights until further notice. This may impact on IP study
- supplies and lab sample shipments coming in and out of Thailand
- Domestic flights resumed on 1st May
- Marken vendor approved by QA and may be utilised by sites, if required, as a contingency

General

Novotech office in Bangkok is partially opened although 100% of Novotech staff can work remotely. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation

COVID-19 Trials

• HA and EC have an expedited COVID-19 trials review commitment of 8 weeks

Top sites: High level status (Top 10 sites in Thailand represent 59% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
Maharaj Nakorn Chiang Mai Hospital	Available	by video	Available	Available	by video	Expedited
Srinagarind Hospital	Available	by video	Available	Available	by video	Expedited
Siriraj Hospital	Available	Available	Available	Available	Available	Expedited
Songklanagarind Hospital	Available	by video	Available	Available	by video	Expedited
King Chulalongkorn Memorial Hospital	Available	Available	Available	Available	Available	Expedited
Phramongkutklao Hospital	Available	Available	Available	Available	Available	Expedited
Thammasat Hospital	Available	Available	Available	Available	Available	Expedited
Ramathibodi Hospital	Available	Available	Available	Available	Available	Expedited
Rajavithi Hospital	Available	Available	Available	Available	Available	Expedited

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org


NT NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

Malaysia COVID-19 Snapshot

	Malaysia		United States		
	#	Δ1	#	Δ^1	
Confirmed Cases	194,114	+91%	26,166,201	+34%	
Deaths	707	+57%	 439,517	+30%	
Deaths per 1M	22	+57%	1,323	+30%	
Testing rate per 1M	141,316	-	 916,573	-	





Malaysia Clinical Trial Insights

Feasibility	Majority of sites continue to be very interested in new studies however some delays in response are expected
Ethics and Governance	 EC and HA review ongoing as per schedule now. Health Authority is prioritising COVID-19 applications during this period An expedited review will be given for these studies under pandemic/epidemic status for public health interests. The timeline for expedited review is 20 working days
Recruitment	 Recruitment is ongoing at sites, subject to Principal Investigator's discretion/ Hospital's direction, however this may be impacted by the travel restrictions imposed by the government
Participant visits	Most sites remain open for subject visits, subject to Principal Investigator's discretion/ Hospital's direction
Monitoring	Onsite monitoring visits are not allowed at the moment. Permete monitoring is allowed at most sites with remote SDV limited at certain sites.

IP Supply and

General

- Remote monitoring is allowed at most sites, with remote SDV limited at certain sites.
- delivery
- No restrictions on IP supply to sites by the drug depot
- DTP vendor approved by QA and may be utilised by sites, if required, as a contingency
- The Malaysian government has imposed Movement Control Order (CMCO) until Feb 4th 2021 in almost all states in the country. Only 5 essential economic sectors allowed to operate: manufacturing; construction; service; trade and distribution; and plantations and commodities. Those in non-essential services are to work from home.
- No interstate and inter-district travel are allowed
- 100% of Novotech staff can work remotely. State-of-the-art IT infrastructure with ISO 27001 Information Security
- HA and EC expedite COVID-19 trials on a case by case basis

COVID-19 Trials

Currently Malaysia is participating in the WHO SOLIDARITY trial, with 9 sites, and a phase 3 COVID vaccine trial with 9

Top 10 sites: High level status (Top 10 sites in Malaysia represent 63% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
University Malaya Medical C.	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Kuala Lumpur	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Pulau Pinang	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Ampang	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Umum Sarawak	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Raja Perempuan Zainab II	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Raja Permaisuri Bainun	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Serdang	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Sultan Ismail	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited
Hospital Tengku Ampuan	Available	Available (remotely)	Available	Available	Remote Monitoring	Expedited

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org


NT NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

Singapore COVID-19 Snapshot

	Singapore		United States		
	#	Δ1	#	Δ^1	
Confirmed Cases	59,391 2%		 26,166,201	+34%	
Deaths	29	0%	439,517	+30%	
Deaths per 1M	5	0%	1,323	+30%	
Testing rate per 1M	1,074,652	-	 916,573	-	

(1) change versus previous month



Singapore Clinical Trial Insights

Feasibility	•	Majority of sites continue to be very interested in new studies however some delays in response are expected
-------------	---	--

Ethics and EC and HA review ongoing as per schedule

Governance Singapore HA has released guidance on conduct of clinical trials in relation to the COVID-19 situation

Recruitment Recruitment available for most sites

Participant Subject visits ongoing per normal

visits If remote study visits are to be implemented, this must be notified to HA prior to implementation

Onsite monitoring visits are allowed if pre-arranged with Principal Investigator and Study Coordinator. Monitoring

Only monitors are allowed on site

IP Supply and delivery

General

- No restrictions for IP supply to sites by drug depot
- DTP vendor approved by QA and may be utilised by sites if required

Singapore government has implemented the post Circuit Breaker phase 3 on Dec 28th 2020. Essential businesses are back to normal and people are encouraged to work from home.

100% of Novotech staff can work remotely with office access if required. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation

COVID-19 HA and EC may review COVID-19 trials on expedited basis, on a case-by-case basis **Trials**

Currently there are three COVID-19 trials approved in Singapore and 1 COVID vaccine trial.

Top biotech sites: High level status (Top sites in Singapore represent 100% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
National University Hospital	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	Expedited
Singapore General Hospital	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	Expedited
Changi General Hospital	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	Expedited
National Cancer Centre	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	
Raffles Hospital	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	
Tan Tock Seng Hospital	Available	Available (if pre- arranged)	Available)	Available	Onsite (with pre- arrangement)	Expedited
Khoo Teck Puat Hospital	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	Expedited
Curie Oncology	Available	Available (if pre- arranged)	Available	Available	Onsite (with pre- arrangement)	-

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Statista, Worldometer, Ourworldindata.org


NOVOTECH The Asia Pacific CRO

Status as at: 25th January 2021

India COVID-19 Snapshot

	India		United States	
	# \(\Delta^1 \)		# Δ¹	_
Confirmed Cases	10,702,031	+5%	26,166,201 +34%	
Deaths	153,885	+4%	439,517 +30%	•
Deaths per 1M	111	+4%	1,323 +30%	6
Testing rate per 1M	140,035	-	916,573 -	

(1) change versus previous month



India Clinical Trial Insights

Feasibility	Feasibilities are now progressing normally
Ethics and Governance	 Most of the ethics committees are operating and reviewing clinical trials normally Ethics committees are also advised by Indian Council of Medical Research to review COVID19 trials in expedited manner Indian Council of Medical Research also released draft guidance to allow consenting through e-mail or text messages
Recruitment	 Sites are now open as lockdown is only restricted to containment zones. There are still some restrictions on travel so patient recruitment may still be affected
Participant visits	A majority of top sites allow visits to occur
Monitoring	 Onsite monitoring visits are possible but depending upon approval from the site All top biotech sites allow for remote monitoring
IP Supply and delivery	 IP supply chain is functioning and allow to deliver IP to hospitals as well as directly to participants Major IP storage and distribution companies are operating normally
General	 India has implemented a lockdown which is restricted to specific containment zones, during this time all medical / healthcare facilities remain open with a focus on COVID-19 management 100% of Novotech staff can work remotely. State-of-the-art IT infrastructure with ISO 27001 Information Security accreditation
COVID-19 Trials	Regulatory submissions for all trials are conducted online

The Ministry of Health has implemented expedited timelines for COVID trials review (within 10 working days)

Top 10 sites: High level status (Top 10 sites in India represent 12% of biotech activity)

Site

	Ethics/ Gov	Initiation	Recruitment	Participant visits	Monitoring	trials
King George's Medical Univ.	Available	Available	Available	Available	Remote monitoring	Several studies ongoing
Ruby Hall Clinical Services	Available	Available	Available	Available	Remote monitoring	Several studies ongoing
K.L.E.S. Dr. Prabhakar Kore Hospital	Available	Available (remotely)	Available	Available	Remote monitoring	-
King George Hospital Visakhapatnam	Available	Available partially	Available	IP is been dispensed via courier	Remote monitoring	Several studies in review
Sir Ganga Ram Hospital	Available	Available partially	Available	IP can be dispensed via courier	Remote monitoring	Several studies in review
Postgraduate Institute of Medical Education and Research Chandigarh	Available	Available (remotely)	Available	Available	Remote monitoring	-
Curie Manavata Cancer Centre	Available	Available partially	Available	Available	Remote monitoring	-
Deenanath Mangeshkar Hospital	Available	Available partially	Available	Available	Remote monitoring	Several studies in review
B J Medical College & Sassoon Hospital, Pune	Available	Available	Available	IP can be dispensed via courier	Available (remote and onsite)	Several studies in review

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org

N Novotech-cro.com

COVID-19

NOVOTECH
The Asia Pacific CRO

Status as at: 25th January 2021

The Philippines COVID-19 Snapshot

	The Philippines		United States		
	#	Δ1		#	Δ^{1}
Confirmed Cases	518,407	+11%		,166,201	+34%
Deaths	10,481	+16%	-	39,517	+30%
Deaths per 1M	95	+16%		1,323	+30%
Testing rate per 1M	69,054	-	9	16,573	-

The Philippines: New and cumulative COVID-19 cases by notification date 10,000 New cases (left axis) Cumulative cases (right) 500,000 8,000 400,000 6,000 300,000 4,000 200,000 2,000 100,000 01-Mar 17-Apr 22-Oct 08-Dec 24-Jan 03-Jun 20-Jul 05-Sep

(1) change versus previous month

The Philippines Clinical Trial Insights

• •	
Feasibility	 Majority of sites continue to be very interested in new studies however some delays in response are expected
Ethics and	Philippine FDA issued circular on Emergency Use Authorization for Covid-19 Vaccine in Dec 2020 with 21 days approval
Governance	timeline.
Recruitment	Recruitments have resumed in Metro Manila, Cebu, and other sites located within the General Community Quarantine.
	Most sites have resumed clinical trial activities.
	Ethics require sponsor to cover for PPE cost of subjects in clinical trial & site staff
Participant visits	We are seeing a number of IRB requiring increase of subject travel budget to cover for special transport arrangement
	going to the site
Monitoring	Onsite monitoring now allowed at some sites
	Sites are open to support remote monitoring however this would be assessed on a case-by-case basis
ID Supply and	 Domestic flights have resumed. Inbound flights may still be limited but cargo flights unhampered.
IP Supply and delivery	 Local logistics providers can support distribution of IP to site or direct-to-patient delivery
	 DTP vendor approved by QA and may be utilised by sites, if required, as a contingency
General	General Community Quarantine status for Metro Manila extended to Jan 31st 2021
	100% of Novotech staff can work remotely. State-of-the-art IT infrastructure with ISO 27001 Information Security
	accreditation
	Strong interest in Covid-19 trials due to high of cases in Metro Manila. Philippines participating in WHO Solidarity I
	(treatment) and Solidarity II (vaccine) trials.

COVID-19 Trials

- COVID-19 trials will be treated as priority by Philippine FDA and the Single Joint Research Ethics Board (SJREB)
- Several investigators indicated interest in Covid-19 MAb treatment trial and Covid-19 vaccine trial

Top 10 sites: High level status (Top 10 sites in The Philippines represent 46% of biotech activity)

	Ethics/ Gov	Site Initiation	Recruitment	Participant visits	Monitoring	COVID-19 trials
Davao Doctors Hospital	Available (with exceptions)	Available (with exceptions)	Available (with exceptions)	Available	Available (with exceptions)	Expedited
De La Salle Health Science Institute	Available	Available	Available	Available	Available (with exceptions)	Expedited
Makati Medical Center	Available	Available (with exceptions)	Available (with exceptions)	Available (with exceptions)	Available (with exceptions)	Expedited
St Luke's Medical Center (SLMC) Quezon City	Available	Available (with exceptions)	Available (with exceptions)	Available	Available (with exceptions)	Expedited
National Kidney & Transplant Institute (NKTI)	Available (with exceptions)	Expedited				
Philippine General Hospital	Available	Available	Available	Available	Available	Expedited
Baguio General Hospital	Available (with exceptions)	Expedited				
Manila Doctors Hospital	Available	Available	Available	Available	Available	Expedited
Perpetual Succour Hospital	Available (with exceptions)	Expedited				

Novotech monitors activity for all sites. Please contact your project manager for an update

Sources: Worldometer, Ourworldindata.org